Fresenius continues to reduce complexity and increase efficiency in its global network. In line with #FutureFresenius, the company announces the divestment of Fresenius Kabi’s Calea homecare business in Canada. This includes the divestment of four sites across the country, including the head office in Mississauga, Ontario, as well as the offices in Hamilton, Ontario, Burnaby, British Columbia, and Calgary, Alberta.
The company has sold the Calea business in Canada to Capital Health Partners (CHP), a Canadian-owned and operated healthcare company committed to advancing the delivery of medical supplies, equipment, pharmaceuticals, and pharmacy services across Canada. Fresenius Kabi continues to supply the Canadian market with its broad portfolio of products and thereby remains a close partner to health care delivery in Canada.
Fresenius continues to reduce complexity and increase efficiency in its global network. In line with #FutureFresenius, the company announces the divestment of Fresenius Kabi’s Calea homecare business in Canada. This includes the divestment of four sites across the country, including the head office in Mississauga, Ontario, as well as the offices in Hamilton, Ontario, Burnaby, British Columbia, and Calgary, Alberta.
The company has sold the Calea business in Canada to Capital Health Partners (CHP), a Canadian-owned and operated healthcare company committed to advancing the delivery of medical supplies, equipment, pharmaceuticals, and pharmacy services across Canada. Fresenius Kabi continues to supply the Canadian market with its broad portfolio of products and thereby remains a close partner to health care delivery in Canada.
The global healthcare company Fresenius is collaborating with other companies and academic institutions with the goals of accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe. Led by Fresenius, the newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will focus on efforts to develop a modular, hospital-based platform capable of manufacturing personalized cell therapies in just a few days, rather than weeks. The project is a public-private partnership, with €8 million in funding provided by the EU through the Innovative Health Initiative (IHI). It leverages technology originally developed by the Cell and Gene Therapy team of Fresenius Kabi, part of Fresenius.
Read the full press release here.
Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly
Development project focused on a hospital-based modular platform, based on technology initially developed by Fresenius Kabi
The EASYGEN project is a public-private partnership, with €8 million backed by EU funding through the Innovative Health Initiative
Important step in #FutureFresenius program
The global healthcare company Fresenius is collaborating with other companies and academic institutions with the goals of accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe. Led by Fresenius, the newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will focus on efforts to develop a modular, hospital-based platform capable of manufacturing personalized cell therapies in just a few days, rather than weeks. The project is a public-private partnership, with €8 million in funding provided by the EU through the Innovative Health Initiative (IHI). It leverages technology originally developed by the Cell and Gene Therapy team of Fresenius Kabi, part of Fresenius.
Dr. Christian Hauer, President MedTech at Fresenius Kabi, said: “This project contributes to expanding our MedTech platform, making it an important step on our path to #FutureFresenius. The aim is not only to develop cutting-edge medical technologies, but also to make them available quickly, safely, and close to the patient. In this way, we are actively working to shape the healthcare of tomorrow.”
“EASYGEN brings together physicians, researchers, and partner institutions from across Europe with the goal of collaboratively advancing innovative, personalized therapies such as CAR-T cells for cancer treatment. Automation can help reduce production complexity of these therapies, with the aim of making it easier to scale these life-saving treatments and improve patient access,” added Prof. Dr. med. Ralf Kuhlen, Chief Medical Officer at Fresenius.
CAR-T therapy is a breakthrough treatment that involves genetically modifying a patient’s T cells to target cancer. It requires complex, time-intensive production in specialized facilities often far from patients. Limited manufacturing capacity and supply chain delays can potentially prevent timely patient access. Despite clinical eligibility, access to CAR-T cell therapy remains limited for patients across Europe. This is particularly evident in diffuse large B-cell lymphoma (LBCL), a type of cancer that is one of the most common indications: Across five European countries, the average treatment rate is below 20%. While approximately 30% of eligible patients receive CAR-T therapy in France, the figure drops to just 11% in Italy.1
Fresenius is actively involved in cell and gene therapy. Fresenius Kabi provides medical technology for these therapies, including automated cell processing systems such as Lovo and Cue. Fresenius Helios, for example, at its Helios Hospital Berlin-Buch, has been offering CAR-T cell therapy as a standard treatment for relapsed cases since 2019. The clinic is also conducting clinical trials to further explore the potential of CAR-T therapies. Quirónsalud, Fresenius’ Spanish hospital business, has established specialized oncology units that offer CAR-T cell therapy as part of their advanced cancer treatment portfolio, particularly for hematologic malignancies.
EASYGEN is led by Fresenius and academically co-led by Fraunhofer Institute, IZI, Leipzig – one of Europe’s foremost immunotherapy research centers in collaboration with Prof. Dr. Michael Hudecek, a leader in CAR-T cell engineering and Prof. Dr. Ulrike Köhl, a pioneer in translational cellular immunotherapies.
1 IQVIA Institute for Human Data Science. (03/ 2025). Achieving CAR T-cell Therapy Health System Readiness: An Assessment of Barriers and Opportunities.
Consortium partners – 18 organizations across 8 countries
Industry & clinical leaders: Fresenius (Coordinator, Germany), Helios Hospital Berlin-Buch (Germany), Quirónsalud (Spain), Fenwal Inc. (USA), Cellix Ltd. (Ireland), Charles River (Germany), Pro-Liance Global Solutions (Germany), TQ Therapeutics (Germany), Philips Electronics Nederland B.V. (Netherlands).
Academic & research institutions: Fraunhofer IESE (Germany), Fraunhofer IZI (Germany), Helmholtz-Zentrum Dresden-Rossendorf (Germany), Technical University of Denmark (Denmark), Frankfurt School of Finance & Management (Germany), European Society for Blood & Marrow Transplantation (Netherlands), Bar-Ilan University (Israel), University of Glasgow (UK), University of Navarra (Spain).
* * *
Learn more about CAR-T cell therapy: Interview Prof. Bertram Glaß, Chief Physician for Hematology and Cell Therapy at Helios Hospital Berlin-Buch: www.fresenius.com/car-t-cell-therapy
* * *
About EASYGEN
EASYGEN is a five-year research project supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194710. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and industry partners. Selected under the IHI call “User-centric technologies and optimized hospital workflows for a sustainable healthcare workforce”, the project aims to develop an integrated, automated platform that enables point-of-care CAR-T cell manufacturing—cutting production time, reducing costs, and expanding access to next-generation immunotherapies.
Disclaimer: Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
Copyright: Johannes Krzeslack
Image Description
In the front row, from left to right: Dr. Sonja Steppan (Easygen Principal Investigator, Fresenius SE), Prof. Dr. Michael Hudecek (Fraunhofer IZI), Theresa Kagerbauer (TQ Therapeutics), Dr. Agnes Vosen (HZDR), Christopher Wegener (Fresenius Kabi), Vaclovas Radvilas (EBMT), Dr. Julia Schüler (Charles River), Dr. Julia Busch-Casler (HZDR), Nicole Spanier-Baro (Fraunhofer IESE), Vivienne Williams (Cellix Limited), Prof. Dr. Bertram Glaß (Helios), Prof. Dr. Ulrike Köhl (Fraunhofer IZI), Rebecca Scheiwe (Fresenius SE). In the back row, from left to right: Prof. Dr. Ralf Kuhlen (Fresenius SE), Prof. Dr. Jens O. Brunner (DTU), Dominik Narres (Fresenius SE), Thomas Brzoska (Pro-Liance Global Solutions), Dr. David Krones (Fraunhofer IZI), Dr. Sabine Bertsch (Pro-Liance Global Solutions), Dr. Ralf Hoffmann (Philips), Christin Zündorf (TQ Therapeutics), Dr. Anna Dünkel (Fraunhofer IZI).
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
Quality excellence and integrity
In everything we do, we have a clear compass: it is all about doing the right thing.
As a global healthcare Group, our goal is to save lives and improve the quality of life for our patients. To achieve this, we provide access to affordable, innovative medical products and high-quality clinical care, and create a framework for the safe handling of medicines.
Integrity is the cornerstone of trust − within our organization and in every interaction with patients, partners, regulators, and society at large. At Fresenius, we foster a culture where ethical behavior is embedded in everything we do. Guided by clear principles, we don’t simply comply with standards − we act with conviction. Our commitment to respect human rights is an integral part of our social responsibility.
The Ethical Foundation of our Sustainability Framework encompasses the following focus topics:
For us, quality excellence means a commitment to providing leading product and service quality and safety, driven by continuous improvement and effectiveness. We foster innovation that delivers meaningful benefits for patients.
Since our operations encompass healthcare services, pharmaceuticals, and medical technology, the quality requirements naturally vary. Our quality management systems are specifically designed to address these diverse needs, meeting both internal standards and external requirements. We ensure this through robust processes and comprehensive training programs across all areas of our business. To track our performance, we use clearly defined quality indicators and targets. These are not only embedded in our daily work but also tied to the variable compensation of our Management Board.
➔ Read more in our Sustainability Statement.
Innovation is key to meeting the needs of our patients – today and in the future. For us, it is a driving force behind improving treatment options, streamlining workflows, and delivering high-quality healthcare solutions. Our integrated approach spans the entire value chain and focuses, among other things, on initiatives that enhance therapies and patient experience through research, telemedicine, and artificial intelligence.
The quality of our products, services, and therapies is the basis for optimal medical care.
➔ Read more in our Sustainability Statement.
We are committed to respecting human rights.
Patients, doctors, nursing and administrative staff rely on our products, concepts, and solutions. Around 176,000 employees place their trust in Fresenius as an employer. At the same time, we rely on thousands of people worldwide who work for our suppliers and business partners in our value chain.
Our Human Rights Program is based on internationally recognized standards and frameworks, including the Universal Declaration of Human Rights, the Core Labor Standards of the International Labour Organization, the UN Guiding Principles on Business and Human Rights (UNGPs), and the OECD Due Diligence Guidance for Responsible Business Conduct.
Our commitment to respect human rights is an integral part of our responsibility as a global healthcare company.
➔ Read more on our Human Rights page.
We are committed to high ethical business standards for the benefit of patients, employees, and the planet.
We believe in doing the right thing. That means acting not only in line with legal requirements, but also in accordance with industry codes, internal policies, and our values – the Fresenius Principles. Internal and external controls help ensure compliance and safeguard the trust our stakeholders place in us.
No matter the role, our work is grounded in the Fresenius Code of Conduct.
➔ Read more on our Compliance page.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
The smart future of healthcare
Artificial intelligence (AI) is driving the healthcare industry – and Fresenius is leveraging its capabilities to enhance the patient experience and broaden treatment options. Smart automation processes are a key factor and we develop intelligent analysis tools to support medical professionals in areas such as evaluation of diagnostic tests.
-
Breakthrough success in breast cancer treatment
Fresenius is committed to researching and developing new therapeutic approaches. One current area of research is a worldwide long-term study on antibody drug conjugates (ADCs) in breast cancer treatment. Find out about the promising results and the potential of this new therapy.
-
AI in colorectal cancer screening
Colon cancer is the second most common form of cancer in women and men. However, the risk of developing colon cancer can be reduced by regular screening. The gold standard is colonoscopy, which is recommended in Germany for men from the age of 50 and for women from the age of 55.
-
Safety Excellence Award:
On the World Day for Safety and Health at Work, the Ministry of Labor in the Dominican Republic conferred an award on our Haina site for its commitment and services for health and safety in the workplace.
Our commitment to a healthy planet
As a healthcare company, we operate in a special field of tension. On the one hand, we want to do our best to reduce potentially adverse environmental impacts to a minimum. On the other hand, we must never lose sight of the strict requirements that are placed on patients’ safety and hygiene. Our aim is to promote human health while further reducing our ecological footprint.
People need a healthy home – today and tomorrow. By reducing the environmental impact of our activities, we want to play our part in mitigating climate change and conserving natural resources.
The Planet Dimension of our Sustainability Framework encompasses the following focus topics:
We have a clear goal: to decarbonize our operations and our value chain.
Fresenius manufactures medical products and operates healthcare facilities, which inevitably results in energy consumption and associated greenhouse gas emissions. In production, for example, the machines and containers have to be sterilized, and in our hospitals a wide variety of technical systems are in constant operation. This presents us with special challenges: On the one hand, we want to reduce our energy demand as far as possible and on the other hand, we must always guarantee the safety of patients in our facilities and ensure a stable supply of energy in our production.
We want to live up to our responsibilities and help achieve the goal of the Paris Climate Agreement: Our climate targets aim to limit global warming to 1.5 °C. All our climate protection activities contribute to our long-term objective of attaining net zero by 2050: This requires a company to reduce its avoidable greenhouse gas emissions, while unavoidable emissions must be offset by removing an equivalent amount from the atmosphere and storing it for the long term.
Within our own operations, we are committed to reducing our Scope 1 and Scope 2 emissions by 50% by 2030.
The decarbonization of our value chain is a decisive factor on our long-term path to net zero. Scope 3 emissions include greenhouse gases that are released indirectly in our upstream and downstream value chains – such as from purchased raw materials or at the end of the life of sold products.
Climate change is also a health issue. Rising temperatures, more frequent heatwaves and changing weather patterns directly affect people's health, particularly vulnerable groups such as the elderly, chronically ill, and children. Heat stress can lead to circulatory problems, dehydration and an increased risk of death. At the same time, climate change contributes to the spread of infectious diseases, for example by introducing new vectors such as mosquitoes or contaminating water sources. As a healthcare company, we therefore consider it our responsibility to not only react to the effects of climate change, but also actively contribute to mitigating it. After all, climate protection is health protection.
We place particular emphasis on preserving water quality. In water-stressed areas, we are especially committed to reducing our water withdrawal.
Water is one of our most valuable resources. As a healthcare company, we are dependent on water: We need drinking water of the highest quality to ensure safe patient care. It is crucial for hygiene and well-being. We also use water in the production of our pharmaceutical products – as process water as well as product component. The quality requirements for this water are even higher than those for drinking water.
It is our ambition to avoid or minimize any negative impact on the environment that may arise from our direct business operations or from downstream activities. This also includes avoiding unnecessarily polluting the sources from which we obtain water or into which we discharge our wastewater.
At Fresenius, we focus on reducing our waste and embedding circular principles into product design and packaging solutions.
We are committed to conserving natural resources wherever possible. In doing so, we always have to strike a balance between resource efficiency and hygiene requirements. Disposable items are often used in clinics for hygienic reasons. Our options for saving resources are limited here. There are also strict regulations for pharmaceutical packaging. Our most important levers for conserving resources are therefore developing durable and resource-saving products, reusing resources wherever possible, and disposing of waste safely and systematically.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
The journey of water in production
Water is essential for life on earth. As a healthcare company, we also rely on clean water being readily available. Visit a production site of Fresenius Kabi to find out about the role water plays in manufacturing of our healthcare products.
-
Climate change and health
Climate change not only leads to an increase in extreme weather phenomena such as heat, storms, floods and flooding caused by heavy or continuous rainfall, but also increases potential health risks.
-
Project DOME
Setting targets and working to become a more sustainable company is only possible if you know what you are looking at and talking about. Therefore, we, at Quirónsalud, brought a project to life that allows us to monitor the energy, water, and gas consumption of our Spanish hospitals in one system.
-
Redesign of green spaces in Hildesheim
Helios hospital Hildesheim is gradually redesigning its approximately 24,000 m² of outdoor areas on the hospital grounds in a sustainable manner. This includes creating biodiversity, habitats and a food supply for birds and insects as well as beautiful recreational areas for patients and staff.
-
Collaboration to increase efficiency
The Global Competence Cluster Energy, Water & Waste Management was established as an additional component to the existing management systems in 2019. The aim is to offer experts at all the production sites a platform where they can share innovative ideas and proposals.
Excellent care – Human to Human
Our pledge, Committed to Life, underlines our mission: To save lives and improve patients’ health and quality of life. Our employees put this promise into practice every day – whether in direct contact with patients or behind the scenes in administration and production.
People are at the heart of our business activities. We accompany patients through various stages of their lives – sometimes even on a lifelong basis. In doing so, we treat them with respect, as equals, and with a deep understanding of their needs.
We want to promote access to high-quality healthcare and medicine. To this end, we focus on innovative and digital treatment options that enable us to reach even more people.
With the commitment they demonstrate day and night, our employees are a key factor in our success. We want to offer them the best possible working environment, where they can develop and reach their full potential.
Our Outreach
We treated
~ 26 m
patients in our hospitals in 2024.
We served
450 m
patients with our healthcare products in 2024.
The Human Dimension of our Sustainability Framework encompasses these focus topics:
Patient centricity at Fresenius means prioritizing multifaceted patient needs and experiences by providing holistic care through market-leading medical products and services – in inpatient and outpatient settings.
Every year, millions of people entrust us with their most precious asset: their health. With our expertise, we accompany our patients through health and illness: from human to human.
We set out to make our treatments more successful by providing high-quality care. This can help to shorten our patients’ hospital stays, enhance their quality of life – and improve patient satisfaction.
➔ Read more in our Sustainability Statement.
Digitalization plays a crucial role in shaping personalized and efficient processes in our hospitals as well as in the use of our products. We continuously digitize existing processes and introduce new digital workflows. Further, we leverage the capabilities of Artificial Intelligence to enhance the patient experience and expand treatment options, while ensuring its responsible use in accordance with ethical standards, data privacy regulations, and transparency principles.
➔ Read more in our Sustainability Statement.
We strive to provide affordable, high-quality products and services that are accessible and enable significant savings to healthcare systems.
Our range of products and services includes the services of a broad network of clinics as well as high-quality pharmaceuticals and medical devices. We also use digitalization opportunities and develop new forms of therapy. In this way, we aim to reach as many people as possible with our healthcare services and products.
We are dedicated to advancing global health by prioritizing patient well-being and empowering employees. Our growing portfolio includes pharmaceuticals – generics and biosimilars – that offer cost-effective alternatives to originator drugs, and our MedTech and Nutrition products that establish a solid foundation for patient care and recovery.
Ensuring that our products are available is vital to patient care. We continuously invest in our global manufacturing network to maintain a reliable and resilient supply of life-saving therapies. By strengthening our supply infrastructure, we help to prevent disruptions and enhance healthcare delivery worldwide.
➔ Read more in our Sustainability Statement.
Strengthening our purpose-driven performance culture to attract, develop, and retain a motivated workforce is a key priority – because our employees are the foundation of delivering excellent medical care.
Committed to Life – our nearly 180,000 employees put this promise into practice every day: whether in direct contact with patients, relatives, and business partners or behind the scenes in administration and production.
As an employer, it is our responsibility to provide good and safe working conditions for our employees. We seek direct interaction with our employees – because their wide variety of experiences and views help us to constantly improve. Providing our employees with the best possible support in the various phases of their careers while also promoting their commitment and development is very important to us.
Our Team
179884
people were employed by the Fresenius Group in 2024.
41.1
– was the average age of our employees in 2024.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
The smart future of healthcare
Artificial Intelligence is driving the healthcare industry – and Fresenius is leveraging its capabilities to enhance the patient experience and broaden treatment options.
-
Nutrition – the key to human health
“You are what you eat.” This familiar saying highlights the importance of nutrition for human health. Food is our source of energy, nutrients, vitamins and trace elements. These ingredients provide us with everything we need to stay healthy and to recover when we are sick.
-
Relieving the pressure in the ED
Overcrowded, and really long waiting times – being in the emergency department (ED) sometimes feels worse than the injury or sickness itself. At Quirónsalud, we are continuously working to improve this experience for everyone involved.
-
Angels for Change
Fresenius Kabi USA received the Drug Shortage Guardian Award 2024 from the Angels for Change in May 2024. The mission of this organization is to look after patients during drug shortages.
-
A strong team for the future
What would a hospital actually be without nursing staff? There’s a clear answer: the hospital would shut down. Helios is the largest hospital operator in Germany with more than 80 clinics, and has developed an array of ideas to attract the best candidates.
-
Virtual reality training at Fresenius Kabi
With the introduction of virtual reality training at Fresenius Kabi, new employees in cleanrooms are able to familiarize themselves with the cleanroom setting in a realistic way before physically entering one.
Our Sustainability Framework
Our mission is to save and improve human lives. We focus on opportunities that arise from sustainable business practices and use them to drive measurable progress. This approach is built on a unique corporate legacy that spans more than a century. We are guided by strong principles and a clear direction for the future.
Our Sustainability Framework guides our daily actions and shapes how we integrate sustainability into our business.
We focus on three core dimensions:
“For us, sustainability is not just a buzzword. It's our responsibility and our strength. It makes us competitive and resilient and ensures our success. Both today and tomorrow.”
Dr. Michael Moser, Member of the Fresenius Management Board responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and Fresenius Vamed
Our Goals and Progress
Since we can only improve what we can understand and control, we have set ourselves goals along our business activities – for the Group as a whole and for the individual operating companies.
At Fresenius, sustainability is an important responsibility of the Management Board: As a key component of our business strategy, sustainability targets are also included in the variable compensation of the Management Board.
Our Sustainability Governance
Effective governance is essential for us to understand and actively manage our activities. It provides the structure and accountability needed to ensure that our sustainability ambitions are not just aspirations, but actions. Through an integrated approach, we turn isolated initiatives into meaningful progress.
Clear ownership and strong collaboration
At Fresenius, overall responsibility for sustainability lies with the Fresenius Management Board member responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and Fresenius Vamed.
The Group Sustainability function serves as the central competence center for sustainability across the Group. It monitors regulatory developments, identifies material topics, defines strategic priorities and opportunities to drive implementation of our Sustainability Framework. It supports the Group-wide rollout of sustainability initiatives. It is also responsible for sustainability-related internal and external stakeholder communication and, together with Global Accounting, for non-financial reporting.
The Group Sustainability Committee defines the company-wide approach, monitors progress, and oversees its implementation – both overall and across the individual focus topics. Dedicated working groups throughout the organization drive these topics forward and ensure their operational execution.
The Management Board and the Supervisory Board review the progress and the results of the sustainability management across the Group.
"We focus our sustainability efforts where they create the greatest impact for people, the planet, and our business. With clear goals and close monitoring, we systematically embed sustainability across every part of our operations."
Sarah Tix, Head of Group Sustainability, Fresenius Group
Our Sustainability Advisory Board
Fresenius has appointed an independent Sustainability Advisory Board. Four leading international experts from science, business, and consulting are supporting us in further developing our related activities.
Image from left to right: Fabian Kienbaum, Dr. Fiona Adshead, Dr. Michael Moser (Member of the Management Board), Anahita Thoms (Chair) and Prof. Dr. Judith Walls.
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Meeting of the Sustainability Advisory Board at Quirónsalud: Human-Centered Care in Focus
How digital innovation and value-based healthcare are transforming the provision of healthcare services and enabling patient-centered, sustainable solutions was the focus of Fresenius’ Sustainability Advisory Board meeting held in Madrid in June 2025.
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Sustainability at Fresenius: Five Questions for Sarah Tix, Head of Group Sustainability
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Meeting of the Sustainability Advisory Board at Fresenius Kabi: Driving Sustainability in Manufacturing
At the first SAB meeting of 2025, held at the Fresenius Kabi production site in Friedberg, Germany, a range of topics related to advancing our sustainability efforts, especially in manufacturing, were discussed – from water management to human rights due diligence.
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Climate Protection: Three questions for Mapi Henríquez de Armas, Director Sustainability at Quirónsalud
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
You would like to learn more about the specific sustainability activities of our operating companies? Have a look at their dedicated websites.
Members of the Management Board of Fresenius Management SE (General Partner):
Michael Sen, 56, became Chairman of the Management Board of Fresenius (equivalent to President and CEO) on October 1, 2022. He joined Fresenius in April 2021 as Chairman of the Management Board of Fresenius Kabi. Before joining Fresenius Kabi, Michael Sen was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin.
Pierluigi Antonelli, 58, joined the Management Board of Fresenius in March 2023 with responsibility for Fresenius Kabi. In his previous role since 2019, he was the CEO of Angelini Pharma, a company of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States and across Europe.
Sara Hennicken (45) was appointed CFO of Fresenius as of September 1, 2022. She joined the Group in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Previously, she spent 14 years in investment banking, including nine years at Deutsche Bank, lastly as Managing Director and Senior Client Executive in Corporate Finance Coverage before moving to Fresenius. Between 2005 and 2010 she worked for Citigroup in Frankfurt and London. Sara Hennicken studied economics in Germany and in the United States.
Robert Möller, 58, joined the Management Board of Fresenius in September 2023 with responsibility for Fresenius Helios. Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master's degree in health care management, he switched to hospital management while continuing to work as a physician.
Michael Moser (48) joined the Management Board of Fresenius in July 2023. He is responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and Fresenius Vamed. After starting his career at Baker McKenzie, he joined E.ON SE in 2008. During this time, he inter alia became member of the Management Board of the stock listed company ENEVA in Brazil, steered the listing of Uniper and served as Deputy CEO and CFO of Enerjisa, the stock listed leading energy company in Turkey. He has received university degrees in law and business economics in Germany, USA, UK, Switzerland and China.
Contact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
board@fresenius.com
In 2024, Fresenius established the Sustainability Advisory Board (SAB), an external body of renowned experts. Leveraging their expertise, SAB members support the further development of our sustainability efforts both collectively and individually by engaging with relevant experts and executives from different parts of our organization on specific matters within their areas of specialization.
Members
Anahita Thoms (Chair)
The head of Baker McKenzie’s international trade practice in Germany is a member of the EMEA Steering Committee for Compliance & Investigations and Global Lead Sustainability Partner for the Industrials, Manufacturing, and Transportation industry group. She is a member of the National Committee of UNICEF Deutschland and of the Board of Directors of Atlantik-Brücke. She was also a member of the German government’s Sustainable Finance Advisory Board and the ABA International Human Rights Steering Committee.
Dr. Fiona Adshead
The former Deputy Chief Medical Officer of the UK Government is a leading expert on sustainability and health. She is currently Chair of the Sustainable Healthcare Coalition, an organization that brings together partners to promote sustainable healthcare.
Fabian Kienbaum
The managing partner at Kienbaum focuses on advising family businesses on governance and succession issues. He is also the author of publications on leadership and modern working environments.
Prof. Dr. Judith Walls
The Chair of Sustainability Management and Director of the Institute for Economy and Ecology (IWÖ) at the University of St. Gallen (HSG) conducts research at the interface of economy and ecological sustainability.
Updates from the Sustainability Advisory Board
In regular meetings, our executives, experts, and members of the Sustainability Advisory Board come together to discuss key questions related to the focus areas of our Sustainability Framework, its implementation, and further development. Explore articles below to learn more.
-
Advancing human-centered care
How digital innovation and value-based healthcare are transforming the provision of healthcare services and enabling patient-centered, sustainable solutions was the focus of Fresenius’ Sustainability Advisory Board meeting held in Madrid in June 2025.
-
Driving Sustainability in Manufacturing
At the first SAB meeting of 2025, held at the Fresenius Kabi production site in Friedberg, Germany, a range of topics related to advancing our sustainability efforts, especially in manufacturing, were discussed – from water management to human rights due diligence.